Wuxi Hexia Chemical Company

14/05/2025

How Resmetirom Stacks Up Against GLP-1 and FGF21 Treatments

Compare Resmetirom, GLP-1, and FGF21 for NASH. Resmetirom excels in reducing liver fat and fibrosis, while GLP-1 and FGF21 target metabolism and inflammation.

02/01/2025

Explore dexketoprofen trometamol: its chemical structure, therapeutic uses, clinical efficacy, safety profile, manufacturing standards, and market status by Wuxi Hexia Chemical Company.

Explore dexketoprofen trometamol: its chemical structure, therapeutic uses, clinical efficacy, safety profile, manufacturing standards, and market status by Wuxi Hexia Chemical Company.

27/12/2024

05/12/2024

Learn about Dexketoprofen/Tramadol 25mg/75mg: indications, dosage, side effects, drug interactions, clinical trial results, and safety guidelines for effective pain management.

02/12/2024

Discover Tirzepatide's metabolic and cardiovascular benefits, clinical evidence, safety profile, and FAQs for effective diabetes and obesity management.

29/11/2024

Explore the latest Dexketoprofen-Trometamol research: studies, methods, results, safety, clinical applications, and comprehensive pharmaceutical insights.

28/11/2024

Comprehensive guide on Dydrogesterone: uses, benefits, dosage, side effects, comparisons, FAQs, and latest research for informed healthcare decisions.

14/10/2024

&Ingredients2024
www.hexiachem.com

Wuxi Hexia Chemical is a leading international enterprise specializing in the import and export of APIs and pharmaceutical intermediates. Through enduring collaborations with over 1500 renowned pharmaceutical enterprises domestic and abroad, we have fostered a culture of trust and mutual growth, which leads us to a crucial role in the global healthcare supply chain.

Time: November 19-22, 2024
Venue: Crocus Expo IEC Russia
Booth: A2001

The Russian Pharmaceutical Raw Materials and Pharmaceutical Machinery Exhibition (Pharmtech & Ingredients) will be held from November 19th to 22nd, 2024 at the Krokus International Convention and Exhibition Center in Moscow, Russia. This exhibition is the most professional and largest pharmaceutical industry exhibition in Russia and the CIS countries. Pharmtech focuses on pharmaceutical equipment, and Ingredients+ focuses on pharmaceutical raw materials and ingredients. Displaying the most complete and comprehensive technology and equipment in the industry, including pharmaceutical raw materials, quality control, laboratory equipment, transportation technology and storage technology.

28/08/2024

www.hexiachem.com

Wuxi Hexia Chemical is a leading international enterprise specializing in the import and export of APIs and pharmaceutical intermediates. Through enduring collaborations with over 1500 renowned pharmaceutical enterprises domestic and abroad, we have fostered a culture of trust and mutual growth, which leads us to a crucial role in the global healthcare supply chain.

Time: October 8-10, 2024
Venue: Fiera Milano, Italy
Booth: 2A111

CPHI Milan is a major pharmaceutical event, part of the global CPhI series, focusing on pharmaceutical ingredients and technology. It brings together professionals from around the world, providing opportunities for networking, industry insights, and showcasing the latest innovations in the pharmaceutical sector.

24/07/2024

**Wuxi Hexia company 2024 mid-year summary meeting concluded successfully**
With the end of the first half of 2024, our company held a semi-annual summary meeting here. In the past six months, we have experienced many challenges and opportunities, and the team has demonstrated excellent collaboration and innovation. Now we will summarize our work, share experiences with you, analyze deficiencies, and make better plans for the work in the second half of the year.
This meeting not only demonstrated the efforts and achievements of our team, but also allowed us to gain many valuable experiences and friendships in the exchange. Thank you to every participant for your active participation and enthusiastic support. It is because of everyone's joint efforts that the event was able to proceed smoothly.
In addition to the meeting, we organized a number of team activities, not only to enhance mutual understanding, but also to enhance the cohesion and cooperation of the team through interesting team-building games. Everyone actively participated and enjoyed the fun!
In the reports and discussions of various departments, we have seen many highlights, and of course there will be shortcomings. In the next work, we must continue to maintain our strengths, improve our shortcomings, and transform this harvest into the driving force for future work. The intensification of market competition and the changes in customer needs require us to constantly innovate and adjust our strategies to adapt to the rapidly changing market environment. Looking forward to the second half of the year, we will continue to increase our marketing efforts, optimize service processes, and enhance customer experience. At the same time, we will strengthen internal collaboration and promote cross-departmental cooperation to achieve more efficient resource utilization. Let's work together to create a better tomorrow! Thank you all for your participation and dedication! I hope everyone will continue to work hard in the second half of the year to create better results!🥳

13/06/2024

**Celebrating the Success of the 29th Annual Conference of the China Biopharmaceutical Association**
Congratulations to the successful conclusion of the 29th Annual Conference of the China Biopharmaceutical Association (CBA). This Conference aims to promote cooperation and innovation in the biopharmaceutical industry, and many important guests from academia, government and business attended the meeting.
Dr. Bai represented our company in this important Conference. During the Conference, Dr. Bai actively interacted with many distinguished guests and professionals to exchange knowledge and discuss the latest trends and innovations in the industry. Through on-site exchanges, we not only deepened our understanding of the development trends of the industry, but also laid a good foundation for future scientific research cooperation. Our company will continue to increase R&D investment, and is committed to providing you with better quality biopharmaceutical products and services, and contribute to the development of the industry.
In the future, we will actively participate in CBA's subsequent academic exchange activities, continue to pay attention to the latest developments in the biopharmaceutical industry, and contribute to promoting cooperation and exchanges in the field of biopharmaceutical science and technology between China and the United States.